These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25639617)

  • 21. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
    Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sunitinib effective for rare thymus cancer.
    Cancer Discov; 2015 Apr; 5(4):340. PubMed ID: 25680712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC; Pulido EG; Guillén-Ponce C
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
    J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacia's SU5416 not effective.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):5. PubMed ID: 12113066
    [No Abstract]   [Full Text] [Related]  

  • 26. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?
    Hilbert M; Mary P; Larroquet M; Serinet MO; Helfre S; Brisse H; Coulomb A; Orbach D
    Pediatr Blood Cancer; 2012 Mar; 58(3):475-6. PubMed ID: 22234817
    [No Abstract]   [Full Text] [Related]  

  • 27. Epithelioid hemangioendothelioma of the kidney treated with sunitinib.
    Tolkach Y; Petrov S; Lerut E; Van Poppel H
    Onkologie; 2012; 35(6):376-8. PubMed ID: 22722460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic therapy for von Hippel-Lindau disease.
    Madhusudan S; Deplanque G; Braybrooke JP; Cattell E; Taylor M; Price P; Tsaloumas MD; Moore N; Huson SM; Adams C; Frith P; Scigalla P; Harris AL
    JAMA; 2004 Feb; 291(8):943-4. PubMed ID: 14982909
    [No Abstract]   [Full Text] [Related]  

  • 29. New perspectives: role of Sunitinib in breast cancer.
    Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
    Clin Ter; 2011; 162(3):251-7. PubMed ID: 21717054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
    Wang S; Mou Z; Ma Y; Li J; Li J; Ji X; Wu K; Li L; Lu W; Zhou T
    Biochem Pharmacol; 2015 May; 95(2):98-109. PubMed ID: 25824241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer].
    Zhao X; Meng XY; Sun B; Ding LJ; Jiang ZF; Song ST; Wu SK
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):96-8. PubMed ID: 23648343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.
    Maeng CH; Yi JH; Lee J; Hong JY; Choi MK; Jung HA; Park JO; Park SH; Park YS; Kang WK; Lim HY
    Anticancer Res; 2013 Oct; 33(10):4619-26. PubMed ID: 24123039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppressing effects of sunitinib on allergic rhinitis: previously undefined side effects with therapeutic potential.
    Eechoute K; van Zonneveld M; van Daele PL; van Wijk RG; Mathijssen RH
    J Clin Pharmacol; 2011 Nov; 51(11):1592-5. PubMed ID: 21189307
    [No Abstract]   [Full Text] [Related]  

  • 34. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New perspectives: role of sunitinib in breast cancer.
    Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
    Clin Ter; 2010; 161(5):475-82. PubMed ID: 20949248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sunitinib and hypothyroidism].
    Cohen R; Bihan H; Uzzan B; des Guetz G; Krivitzky A
    Ann Endocrinol (Paris); 2007 Oct; 68(5):332-6. PubMed ID: 17707761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.
    Seandel M; Shia J; Linkov I; Maki RG; Antonescu CR; Dupont J
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6203-4. PubMed ID: 17062698
    [No Abstract]   [Full Text] [Related]  

  • 40. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
    Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
    Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.